Digestive system neuroendocrine neoplasm
MONDO:0024503A neoplasm with neuroendocrine differentiation arising from the digestive system. It includes neuroendocrine tumors (well-differentiated endocrine tumors or carcinoid tumors and well differentiated endocrine carcinomas) and neuroendocrine carcinomas (poorly differentiated neuroendocrine carcinomas, small cell carcinomas, and large cell neuroendocrine carcinomas).
Also known as: alimentary part of gastrointestinal system NET, alimentary part of gastrointestinal system neuroendocrine neoplasm, alimentary part of gastrointestinal system neuroendocrine tumor, alimentary part of gastrointestinal system neuroendocrine tumor, well differentiated, low or intermediate grade, alimentary part of gastrointestinal system neuroendocrine tumour, carcinoid tumor of digestive system, carcinoid tumour of digestive system, digestive system NET
1620 clinical trials for this condition and its sub-types, 52 tagged with Digestive system neuroendocrine neoplasm itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Digestive system neuroendocrine neoplasm
-
Digestive system neuroendocrine tumor, grade 1/2 66 trials · 145 incl. sub-types
10 sub-types
- Pancreatic neuroendocrine tumor 60 trials · 77 incl. sub-types Sub-types →
- Small intestine neuroendocrine tumor, well differentiated, low or intermediate grade 4 trials · 9 incl. sub-types Sub-types →
- Intestinal neuroendocrine tumor G1 5 trials · 8 incl. sub-types Sub-types →
- Neuroendocrine tumor of the colon, well differentiated, low or intermediate grade tumor 0 trials · 5 incl. sub-types Sub-types →
- Gastric neuroendocrine tumor, well differentiated, low or intermediate grade 2 trials · 4 incl. sub-types Sub-types →
- Rectal neuroendocrine tumor 3 trials · 4 incl. sub-types Sub-types →
- Esophageal neuroendocrine tumor 1 trial · 3 incl. sub-types Sub-types →
- Gastrin-producing neuroendocrine tumor 3 trials Sub-types →
- L-cell glucagon-like peptide-producing neuroendocrine tumor 0 trials Sub-types →
- Gallbladder neuroendocrine tumor, grade 1/2 0 trials
-
Pancreatic neuroendocrine neoplasm 9 trials · 85 incl. sub-types
2 sub-types
- Pancreatic neuroendocrine tumor 60 trials · 77 incl. sub-types Sub-types →
- Pancreatic endocrine carcinoma 12 trials Sub-types →
-
Intestinal neuroendocrine neoplasm 7 trials · 21 incl. sub-types
4 sub-types
- Small intestine neuroendocrine neoplasm 0 trials · 9 incl. sub-types Sub-types →
- Intestinal neuroendocrine tumor G1 5 trials · 8 incl. sub-types Sub-types →
- Rectum neuroendocrine neoplasm 3 trials · 6 incl. sub-types Sub-types →
- Colon neuroendocrine neoplasm 0 trials · 5 incl. sub-types Sub-types →
-
Gastric neuroendocrine neoplasm 3 trials · 6 incl. sub-types
2 sub-types
- Gastric neuroendocrine tumor, well differentiated, low or intermediate grade 2 trials · 4 incl. sub-types Sub-types →
- Gastric small cell neuroendocrine carcinoma 0 trials
-
Liver neuroendocrine carcinoma 3 trials
2 sub-types
-
Gallbladder neuroendocrine neoplasm 0 trials
2 sub-types
-
Salivary gland small cell carcinoma 0 trials
Most studied deeper sub-types
-
Can a new drug formulation shrink Hard-to-Treat neuroendocrine tumors?
Disease control CompletedThis phase 2 trial is testing an investigational drug called nab-sirolimus in people with advanced neuroendocrine tumors (NETs) of the gastrointestinal tract, lung, or pancreas. Participants must have had up to two prior lines of therapy (excluding somatostatin analogs) and must …
Phase 2 • Sponsor: Aadi Bioscience, Inc. • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Can a black seed extract boost immunotherapy against a rare cancer?
Disease control CompletedThis pilot trial is testing whether adding NP-101, a compound from black seed oil, to two immunotherapy drugs (nivolumab and ipilimumab) can help control advanced or metastatic extra-pulmonary neuroendocrine carcinoma (EP-NECA) that has progressed after initial treatment. About 1…
Phase 1 • Sponsor: Amr Mohamed MD • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Lutathera under the microscope: how does it perform in real patients?
Disease control CompletedThis study followed 164 adults with advanced, progressive neuroendocrine tumors of the gut or pancreas who were treated with Lutathera (a radioactive drug) in normal hospital settings. Researchers measured how long patients lived without their cancer getting worse and how many tu…
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New hope for rare, aggressive cancer: drug cocktail shows promise in trial
Disease control CompletedThis study tested whether adding the drug bevacizumab (Avastin) to standard chemotherapy (Folfiri) helps people with advanced, aggressive neuroendocrine carcinoma live longer after their first treatment stops working. The trial included 153 adults with inoperable cancer that star…
Phase 2 • Sponsor: Hospices Civils de Lyon • Aim: Disease control
Last updated Jun 26, 2026 13:11 UTC
-
Can acupuncture and ice chips beat chemo nerve damage?
Symptom relief CompletedThis phase 2 trial looked at whether adding acupuncture and acupressure to oral cryotherapy (sucking on ice chips) can reduce nerve pain caused by oxaliplatin chemotherapy in people with gastrointestinal cancers. 78 patients were split into two groups: one got cryotherapy alone, …
Phase 2 • Sponsor: University of Washington • Aim: Symptom relief
Last updated Jun 27, 2026 08:13 UTC
-
German study reveals Real-World use of PRRT for neuroendocrine tumors
Knowledge-focused CompletedThis study looked at 117 people with gastro-enteropancreatic neuroendocrine tumors (GEP-NETs) who received a type of radiation therapy called PRRT in German clinics. Researchers collected information on patient characteristics, treatment timing, and how PRRT was given in everyday…
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
PET scan study hints at new hope for tough gut cancer
Knowledge-focused CompletedThis study looked at 30 adults with a rare, fast-growing type of gut cancer called poorly differentiated neuroendocrine carcinoma. Researchers used a special PET scan (68Ga-DOTATATE) to measure how much of a protein called somatostatin receptor is present on tumors. The goal was …
Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC